A little extract from West Pharma's CEO re commercialising wearable injectors.... if (big if) our company survives to prosper, in a few years time we may come to see Alan Shortall in a different light... the stickiness of products meant we had to spend lots of $$ developing wearable injectors before the competition locked big pharma into their own products.... I can sorta appreciate need for the insane cash burn in the race to secure customers.....some food for thought....
"But your point is a very, very good one, and that is these things take a long time to develop. We worked with our customer on the drug for SmartDose for more than five years, and from some of the other CZ commercial opportunities, the one that we've talked about, that was first started to be developed in 2004, and it came to market in 2016. So, that's a 12-year gestation period. So, the point that you're making is a good one and that is, these are very, very sticky products. Once you're approved, a combination device, you're not only being written into the approval from the primary drug container perspective, which is where West has traditionally been, but also the device that is used to help the drug be self-administered is also written into the approval process. So, you become very, very sticky as it relates to that drug and that customer."
.
- Forums
- ASX - By Stock
- UNS
- Ann: Appendix 4D
Ann: Appendix 4D, page-33
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online